- Home
- TOVX vs CURX Comparison
TOVX vs CURX Comparison
Compare TOVX & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOVX | CURX |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 9.7M |
| IPO Year | 2012 | 2024 |
Fundamental Metrics
Financial Performance| Metric | TOVX | CURX |
|---|---|---|
| Price | $0.16 | $6.21 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 11.2K |
| Earning Date | 08-11-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.07 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.21 |
| 52 Week High | $0.49 | $13.33 |
Technical Indicators
Market Signals| Indicator | TOVX | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 30.94 | 66.52 |
| Support Level | N/A | $4.02 |
| Resistance Level | $0.25 | $7.00 |
| Average True Range (ATR) | 0.02 | 0.43 |
| MACD | -0.00 | 0.12 |
| Stochastic Oscillator | 35.19 | 100.00 |
Price Performance
Historical ComparisonAbout TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.